ViaDerma, Inc. (VDRM) Stock Price & Analysis
ViaDerma, Inc. (VDRM) — price $0.0001 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
ViaDerma, Inc. · VDRM
ViaDerma, Inc. is a specialty pharmaceutical company focused on developing and marketing pharmaceutical products, as well as licensing its technology. Its lead product is Vitastem, a topical antibiotic used for various skin conditions and injuries.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0001 |
| Change on the day | 0.00% |
| Price / earnings (trailing) | 28.74 |
| Shares traded on the day | 4.1K |
Price & events
Other perspectives
Council score for ViaDerma (VDRM): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is ViaDerma (VDRM), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ViaDerma, Inc. (VDRM) is the company analyzed here. In Q3 FY2024 it reported revenue of $150,189 and net income of -$321,554.
What do the latest results show for ViaDerma (VDRM)?
Short answer · as of
The most recent reported quarter, Q3 FY2024, carried revenue of $150,189.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2024 | $150,189 | -$321,554 | -$0.0003 (diluted) |
| Q2 FY2024 | $150,131 | -$33,178 | $0.00 (diluted) |
| Q1 FY2024 | $150,490 | $87,615 | $0.0001 (diluted) |
What are the financial strengths and risks for ViaDerma (VDRM)?
Short answer · as of
The distress and quality screens read Altman Z -4.77 · Piotroski F 1. Trailing ratios: ROE -0.5% · ROA 0.3% · current ratio 1.10 · earnings yield 3.5% · free-cash-flow yield 0.1%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -4.77 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-0.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VDRM in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported VDRM in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
ViaDerma Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the VDRM research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for VDRM?
The main risks for ViaDerma, Inc. include its reliance on a single product (Vitastem) for revenue, competition from established pharmaceutical companies, regulatory hurdles and approval delays, patent expiration risks, and the inherent risks associated with OTC market listings.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 8 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com